OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
ABCD2 ScoreACR CriteriaASCVD RiskBurch-Wartofsky Point ScaleCHA2DS2-VAScCURB-65Corrected SodiumFENaGlasgow-Blatchford ScoreHAS-BLEDHEART ScoreISTH DIC ScoreLights CriteriaMaddrey DFNEWS2NRS-2002Osmolality GapPERC RulePadua VTE ScoreRCRI (Lee Score)Ransons CriteriaRevised Geneva ScoreTTKGWells DVT ScoreWells PE Score

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Mandatory first step in the evaluation of any new pleural effusion via diagnostic thoracentesis.
  • Differentiating systemic hydrostatic/oncotic pressure issues (Transudates) from local pleural disease (Exudates).
  • Screening for malignant pleural effusion (MPE) or complicated parapneumonic effusions.

Transudate vs. Exudate Etiology

Transudates
Exudates
CLINICAL INSIGHT

How it Works

Standard Light's Criteria (Serum-Dependent)

  • [object Object]
  • [object Object]
  • [object Object]

The 2026 'Triple Combination' (Blood-Free)

Validated in >7,000 patients (Porcel et al., 2026). If blood sampling is unavailable, an effusion is classified as an EXUDATE if it meets ANY of these PF-only criteria: 1. PF Protein > 3 g/dL 2. PF LDH > 250 IU/L 3. PF Cholesterol > 55 mg/dL

Interpretation Rule

Light's Criteria: Any 1 positive = Exudate (Sensitivity 98%, Specificity ~71%). Triple Combination: Matches accuracy of Light's and reclassifies ~20% of false-positive transudates.

CLINICAL INSIGHT

Practical Pearls

The Diuretic Challenge

Diuretics in CHF patients can 'concentrate' pleural fluid, causing a transudate to meet exudative criteria (pseudo-exudate).

Albumin & Protein Gradients

Malignancy Pearls (CEA Interaction)

  • An LDH ratio > 0.6 is independently associated with false-negative CEA results in malignant effusions (Yang et al., 2025).
  • CEA > 10 ng/mL is highly suggestive of MPE, but 40% of MPEs are CEA-negative.
  • Internet-active patients often prefer allografts in surgical contexts—similarly, in medicine, patients may request 'blood-free' testing (Triple Rule) to avoid repeat venipuncture.
CLINICAL INSIGHT

Evidence Base

The 2026 Validation (Triple Rule)

Revisiting Light's criteria: a validated blood-free triple combination matches diagnostic accuracy in over 7000 patients.

Porcel JM, Porcel L, Palma R, Bielsa S.ERJ Open Research2026
View Source

CEA & Light's Interaction

Effects of Light’s criteria on the diagnostic accuracy of pleural fluid carcinoembryonic antigen concentrations for malignant pleural effusion.

Yang DN, Xu YN, Hu ZD, et al.Scientific Reports2025
View Source

Historical Standard

Pleural effusions: the diagnostic separation of transudates and exudates.

Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr.Annals of Internal Medicine1972
View Source
CLINICAL INSIGHT

Background

Dr. Richard Light's Legacy

Before 1972, the differentiation of effusions was inconsistent, often relying solely on protein levels (>3.0 g/dL). Dr. Richard Light introduced the multi-parameter approach to capture the enzymatic activity (LDH) of inflammatory processes.

Evolution of the Rule

  • 1972: Light's Criteria published; revolutionizes diagnostic thoracentesis.
  • 1990s: Recognition of the 'Diuretic Effect' leads to the adoption of Albumin/Protein gradients.
  • 2010s: Pleural cholesterol gains traction as a standalone high-specificity marker.
  • 2026: The ERS validates the Blood-Free Triple Combination, allowing for PF-only assessment without loss of sensitivity.

Lights Criteria

Light's Criteria: Gold standard for differentiating pleural exudates from transudates. ≥ 1 of 3 criteria met = exudate. Sensitivity 98%, Specificity 83%.
EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Mandatory first step in the evaluation of any new pleural effusion via diagnostic thoracentesis.
  • Differentiating systemic hydrostatic/oncotic pressure issues (Transudates) from local pleural disease (Exudates).
  • Screening for malignant pleural effusion (MPE) or complicated parapneumonic effusions.

Transudate vs. Exudate Etiology

Transudates
Exudates
CLINICAL INSIGHT

How it Works

Standard Light's Criteria (Serum-Dependent)

  • [object Object]
  • [object Object]
  • [object Object]

The 2026 'Triple Combination' (Blood-Free)

Validated in >7,000 patients (Porcel et al., 2026). If blood sampling is unavailable, an effusion is classified as an EXUDATE if it meets ANY of these PF-only criteria: 1. PF Protein > 3 g/dL 2. PF LDH > 250 IU/L 3. PF Cholesterol > 55 mg/dL

Interpretation Rule

Light's Criteria: Any 1 positive = Exudate (Sensitivity 98%, Specificity ~71%). Triple Combination: Matches accuracy of Light's and reclassifies ~20% of false-positive transudates.

CLINICAL INSIGHT

Practical Pearls

The Diuretic Challenge

Diuretics in CHF patients can 'concentrate' pleural fluid, causing a transudate to meet exudative criteria (pseudo-exudate).

Albumin & Protein Gradients

Malignancy Pearls (CEA Interaction)

  • An LDH ratio > 0.6 is independently associated with false-negative CEA results in malignant effusions (Yang et al., 2025).
  • CEA > 10 ng/mL is highly suggestive of MPE, but 40% of MPEs are CEA-negative.
  • Internet-active patients often prefer allografts in surgical contexts—similarly, in medicine, patients may request 'blood-free' testing (Triple Rule) to avoid repeat venipuncture.
CLINICAL INSIGHT

Evidence Base

The 2026 Validation (Triple Rule)

Revisiting Light's criteria: a validated blood-free triple combination matches diagnostic accuracy in over 7000 patients.

Porcel JM, Porcel L, Palma R, Bielsa S.ERJ Open Research2026
View Source

CEA & Light's Interaction

Effects of Light’s criteria on the diagnostic accuracy of pleural fluid carcinoembryonic antigen concentrations for malignant pleural effusion.

Yang DN, Xu YN, Hu ZD, et al.Scientific Reports2025
View Source

Historical Standard

Pleural effusions: the diagnostic separation of transudates and exudates.

Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr.Annals of Internal Medicine1972
View Source
CLINICAL INSIGHT

Background

Dr. Richard Light's Legacy

Before 1972, the differentiation of effusions was inconsistent, often relying solely on protein levels (>3.0 g/dL). Dr. Richard Light introduced the multi-parameter approach to capture the enzymatic activity (LDH) of inflammatory processes.

Evolution of the Rule

  • 1972: Light's Criteria published; revolutionizes diagnostic thoracentesis.
  • 1990s: Recognition of the 'Diuretic Effect' leads to the adoption of Albumin/Protein gradients.
  • 2010s: Pleural cholesterol gains traction as a standalone high-specificity marker.
  • 2026: The ERS validates the Blood-Free Triple Combination, allowing for PF-only assessment without loss of sensitivity.